Silence Therapeutics plc ADR (SLN)
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript
Silence Therapeutics plc (NASDAQ:SLN ) Q4 2024 Earnings Call February 27, 2025 8:00 AM ET Company Participants Gem Hopkins - Vice President, Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Chief R&D Officer Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Capital Markets Richard Law - Goldman Sachs Keay Nakae - Chardan Myles Minter - William Blair Gem Hopkins Good morning and good afternoon, everyone. Thank you for joining us today.
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).
Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'
Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company's main value driver, aims to reduce lipoprotein(a) levels, potentially lowering cardiovascular risks in 20-25% of the global population. Divesiran shows promise in early trials for Polycythemia Vera. Early clinical trial data suggests it can effectively regulate red blood cell production.
Silence: Additional siRNA Drug Data Leads To Next Stages Of Development
Silence Therapeutics plc's positive results achieved from phase 1 SANRECO study using divesiran for the treatment of patients with polycythemia vera. The global polycythemia vera treatment market size is predicted to reach $45 billion by the end of 2036. Full detailed results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, are to be presented at an upcoming medical conference before the end of 2024.
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
Silence Therapeutics (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results
Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets are expected to reach $68.5 billion by 2034. Positive results achieved in the phase 2 ALPACAR-360 study using zerlasiran for patients with elevated levels of Lp[a] at high risk of ASCVD.
